XNASBLFS
Market cap1.23bUSD
Jan 10, Last price
26.61USD
1D
-3.90%
1Q
17.74%
Jan 2017
1,552.49%
Name
BioLife Solutions Inc
Chart & Performance
Profile
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2015‑01 | |
Income | ||||||||||
Revenues | 143,271 -11.43% | 161,759 35.75% | ||||||||
Cost of revenue | 195,623 | 191,975 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (52,352) | (30,216) | ||||||||
NOPBT Margin | ||||||||||
Operating Taxes | 169 | (5,022) | ||||||||
Tax Rate | ||||||||||
NOPAT | (52,521) | (25,194) | ||||||||
Net income | (66,427) -52.49% | (139,805) 1,567.72% | ||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 10,244 | (131) | ||||||||
BB yield | -1.44% | 0.02% | ||||||||
Debt | ||||||||||
Debt current | 13,179 | 4,832 | ||||||||
Long-term debt | 50,232 | 56,987 | ||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 2,328 | |||||||||
Net debt | 6,099 | (8,647) | ||||||||
Cash flow | ||||||||||
Cash from operating activities | (12,498) | (8,489) | ||||||||
CAPEX | (6,381) | (10,385) | ||||||||
Cash from investing activities | 17,837 | (58,117) | ||||||||
Cash from financing activities | 10,591 | 16,317 | ||||||||
FCF | 11,627 | (18,196) | ||||||||
Balance | ||||||||||
Cash | 51,695 | 64,065 | ||||||||
Long term investments | 5,617 | 6,401 | ||||||||
Excess cash | 50,148 | 62,378 | ||||||||
Stockholders' equity | (313,642) | (247,551) | ||||||||
Invested Capital | 697,169 | 41,551 | ||||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 43,719 | 42,481 | ||||||||
Price | 16.25 -10.71% | 18.20 -51.17% | ||||||||
Market cap | 710,437 -8.11% | 773,155 -46.12% | ||||||||
EV | 716,536 | 764,508 | ||||||||
EBITDA | (40,057) | (13,744) | ||||||||
EV/EBITDA | ||||||||||
Interest | 1,812 | 687 | ||||||||
Interest/NOPBT |